Analysts Issue Forecasts for ANIX Q1 Earnings

Anixa Biosciences Inc (NASDAQ:ANIX) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Anixa Biosciences in a research note issued on Thursday, June 11th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.08) per share for the quarter. The consensus estimate for Anixa Biosciences’ current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for Anixa Biosciences’ Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.31) EPS.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03.

ANIX has been the topic of several other research reports. Wall Street Zen lowered Anixa Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Anixa Biosciences presently has a consensus rating of “Hold” and a consensus target price of $8.50.

Anixa Biosciences Stock Up 6.4%

ANIX opened at $2.50 on Friday. The firm has a market cap of $83.83 million, a price-to-earnings ratio of -8.06 and a beta of 0.59. Anixa Biosciences has a 52 week low of $2.32 and a 52 week high of $5.46. The business’s 50 day moving average is $2.78 and its two-hundred day moving average is $3.10.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Segall Bryant & Hamill LLC acquired a new position in shares of Anixa Biosciences in the first quarter valued at approximately $45,000. Renaissance Technologies LLC increased its holdings in shares of Anixa Biosciences by 13.6% in the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock valued at $158,000 after purchasing an additional 7,300 shares during the period. Kestra Advisory Services LLC increased its holdings in shares of Anixa Biosciences by 96.2% in the first quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock valued at $132,000 after purchasing an additional 25,000 shares during the period. Virtu Financial LLC acquired a new position in shares of Anixa Biosciences in the fourth quarter valued at approximately $161,000. Finally, Millennium Management LLC acquired a new position in shares of Anixa Biosciences in the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.